Search research articles
Contact Us
Filters
Showing results (51-60 of 65) with videos related to
Page
of 7
Sort By:
Perfusion
|
December 24, 2010
Biocompatibility and pathways of initial complement pathway activation with Phisio- and PMEA-coated cardiopulmonary bypass circuits during open-heart surgery
A S Thiara, T E Mollnes, V Videm, et al.
Perfusion
|
February 23, 2010
Comparable biocompatibility of Phisio- and Bioline-coated cardiopulmonary bypass circuits indicated by the inflammatory response
A S Thiara, V Y Andersen, V Videm, et al.
Internal Medicine Journal
|
September 19, 2015
Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis
L Cummins, V S Katikireddi, S Shankaranarayana, et al.
The Journal of Thoracic and Cardiovascular Surgery
|
March 30, 1999
Heparin-coated cardiopulmonary bypass equipment. I. Biocompatibility markers and development of complications in a high-risk population
V Videm, T E Mollnes, E Fosse, et al.
The Journal of Thoracic and Cardiovascular Surgery
|
March 30, 1999
Heparin-coated cardiopulmonary bypass equipment. II. Mechanisms for reduced complement activation in vivo
V Videm, T E Mollnes, K Bergh, et al.
Perfusion
|
March 13, 1999
In vitro evaluation of new surface coatings for extracorporeal circulation
S T Baksaas, V Videm, E Fosse, et al.
Scandinavian Journal of Immunology
|
July 4, 1998
Immunoglobulin prolongs survival of pig kidneys perfused ex vivo with human blood
A E Fiane, V Videm, O J Mellbye, et al.
Transplantation Proceedings
|
December 1, 1995
Ex vivo model for xenotransplantation
A E Fiane, V Videm, T Scholz, et al.
Xenotransplantation
|
October 3, 1999
Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts
A E Fiane, T E Mollnes, V Videm, et al.
Transplantation Proceedings
|
March 20, 1999
Prolongation of ex vivo-perfused pig xenograft survival by the complement inhibitor Compstatin
A E Fiane, T E Mollnes, V Videm, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 65) with videos related to
Sort By:
Page
of 7
Perfusion
|
December 24, 2010
Biocompatibility and pathways of initial complement pathway activation with Phisio- and PMEA-coated cardiopulmonary bypass circuits during open-heart surgery
A S Thiara, T E Mollnes, V Videm, et al.
Perfusion
|
February 23, 2010
Comparable biocompatibility of Phisio- and Bioline-coated cardiopulmonary bypass circuits indicated by the inflammatory response
A S Thiara, V Y Andersen, V Videm, et al.
Internal Medicine Journal
|
September 19, 2015
Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis
L Cummins, V S Katikireddi, S Shankaranarayana, et al.
The Journal of Thoracic and Cardiovascular Surgery
|
March 30, 1999
Heparin-coated cardiopulmonary bypass equipment. I. Biocompatibility markers and development of complications in a high-risk population
V Videm, T E Mollnes, E Fosse, et al.
The Journal of Thoracic and Cardiovascular Surgery
|
March 30, 1999
Heparin-coated cardiopulmonary bypass equipment. II. Mechanisms for reduced complement activation in vivo
V Videm, T E Mollnes, K Bergh, et al.
Perfusion
|
March 13, 1999
In vitro evaluation of new surface coatings for extracorporeal circulation
S T Baksaas, V Videm, E Fosse, et al.
Scandinavian Journal of Immunology
|
July 4, 1998
Immunoglobulin prolongs survival of pig kidneys perfused ex vivo with human blood
A E Fiane, V Videm, O J Mellbye, et al.
Transplantation Proceedings
|
December 1, 1995
Ex vivo model for xenotransplantation
A E Fiane, V Videm, T Scholz, et al.
Xenotransplantation
|
October 3, 1999
Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts
A E Fiane, T E Mollnes, V Videm, et al.
Transplantation Proceedings
|
March 20, 1999
Prolongation of ex vivo-perfused pig xenograft survival by the complement inhibitor Compstatin
A E Fiane, T E Mollnes, V Videm, et al.
Page
of 7